U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Malignant pleural mesothelioma

MedGen UID:
208810
•Concept ID:
C0812413
•
Neoplastic Process
Synonym: Malignant mesothelioma of pleura
SNOMED CT: Malignant pleural mesothelioma (254645002); Malignant mesothelioma of pleura (254645002)
 
HPO: HP:0100002
Monarch Initiative: MONDO:0005112

Definition

A malignant mesothelioma originating from cells of the pleura (the thin layer of mesothelium lining the lungs). Pleural mesothelioma is the most common form of mesothelioma. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMalignant pleural mesothelioma

Professional guidelines

PubMed

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆).
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Ann Oncol 2022 Feb;33(2):129-142. Epub 2021 Nov 30 doi: 10.1016/j.annonc.2021.11.005. PMID: 34861373
Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes SM, Alrifai D, Fennell DA
N Engl J Med 2021 Sep 23;385(13):1207-1218. doi: 10.1056/NEJMra1912719. PMID: 34551230
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM
Eur Respir J 2020 Jun;55(6) Epub 2020 Jun 11 doi: 10.1183/13993003.00953-2019. PMID: 32451346

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Mesothelioma: Pleural, 2023

Recent clinical studies

Etiology

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆).
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Ann Oncol 2022 Feb;33(2):129-142. Epub 2021 Nov 30 doi: 10.1016/j.annonc.2021.11.005. PMID: 34861373
Imaging of Malignant Pleural Mesothelioma: Pearls and Pitfalls.
Strange CD, Shroff GS, Ahuja J, Vlahos I, Benveniste MFK, Truong MT
Semin Ultrasound CT MR 2021 Dec;42(6):542-551. Epub 2021 May 8 doi: 10.1053/j.sult.2021.04.011. PMID: 34895610
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Diagnosis

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆).
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Ann Oncol 2022 Feb;33(2):129-142. Epub 2021 Nov 30 doi: 10.1016/j.annonc.2021.11.005. PMID: 34861373
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME
Clin Respir J 2018 Mar;12(3):839-847. Epub 2017 Jan 11 doi: 10.1111/crj.12597. PMID: 27997741
Malignant pleural mesothelioma.
Klepetko W
Wien Klin Wochenschr 2016 Sep;128(17-18):609-10. doi: 10.1007/s00508-016-1039-0. PMID: 27457871
Malignant pleural mesothelioma.
Raja S, Murthy SC, Mason DP
Curr Oncol Rep 2011 Aug;13(4):259-64. doi: 10.1007/s11912-011-0177-9. PMID: 21573909

Therapy

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G
Ann Oncol 2022 May;33(5):488-499. Epub 2022 Feb 3 doi: 10.1016/j.annonc.2022.01.074. PMID: 35124183
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G
Lancet 2021 Jan 30;397(10272):375-386. Epub 2021 Jan 21 doi: 10.1016/S0140-6736(20)32714-8. PMID: 33485464
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P
J Clin Oncol 2003 Jul 15;21(14):2636-44. doi: 10.1200/JCO.2003.11.136. PMID: 12860938

Prognosis

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆).
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Ann Oncol 2022 Feb;33(2):129-142. Epub 2021 Nov 30 doi: 10.1016/j.annonc.2021.11.005. PMID: 34861373
Current surgical treatment of malignant pleural mesothelioma.
Chihara K
Respir Investig 2018 Jul;56(4):265-266. Epub 2018 Jul 3 doi: 10.1016/j.resinv.2017.12.002. PMID: 29980443
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli GL, Soto Parra HJ, Auriati L, Simonassi C
Oncol Res Treat 2017;40(6):364-369. Epub 2017 May 9 doi: 10.1159/000464410. PMID: 28472807
Malignant pleural mesothelioma.
Chen SE, Pace MB
Am J Health Syst Pharm 2012 Mar 1;69(5):377-85. doi: 10.2146/ajhp110281. PMID: 22345416
Pleural mesothelioma.
Astoul P
Curr Opin Pulm Med 1999 Jul;5(4):259-68. doi: 10.1097/00063198-199907000-00015. PMID: 10407698

Clinical prediction guides

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy.
Porta C, Jean D, Blanquart C
Front Immunol 2023;14:1251384. Epub 2023 Jul 24 doi: 10.3389/fimmu.2023.1251384. PMID: 37554331Free PMC Article
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G
Ann Oncol 2022 May;33(5):488-499. Epub 2022 Feb 3 doi: 10.1016/j.annonc.2022.01.074. PMID: 35124183
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME
Clin Respir J 2018 Mar;12(3):839-847. Epub 2017 Jan 11 doi: 10.1111/crj.12597. PMID: 27997741
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Recent systematic reviews

Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review.
Dawson AG, Kutywayo K, Mohammed SB, Fennell DA, Nakas A
Thorax 2023 Apr;78(4):409-417. Epub 2022 Apr 11 doi: 10.1136/thoraxjnl-2021-218214. PMID: 35410957
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM
Eur Respir J 2020 Jun;55(6) Epub 2020 Jun 11 doi: 10.1183/13993003.00953-2019. PMID: 32451346
Radical multimodality therapy for malignant pleural mesothelioma.
Abdel-Rahman O, Elsayed Z, Mohamed H, Eltobgy M
Cochrane Database Syst Rev 2018 Jan 8;1(1):CD012605. doi: 10.1002/14651858.CD012605.pub2. PMID: 29309720Free PMC Article
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
Marulli G, Faccioli E, Bellini A, Mammana M, Rea F
Expert Rev Respir Med 2017 Aug;11(8):649-660. Epub 2017 Jun 12 doi: 10.1080/17476348.2017.1338951. PMID: 28580813
Second line therapy in malignant pleural mesothelioma: A systematic review.
Buikhuisen WA, Hiddinga BI, Baas P, van Meerbeeck JP
Lung Cancer 2015 Sep;89(3):223-31. Epub 2015 Jun 23 doi: 10.1016/j.lungcan.2015.06.018. PMID: 26162564

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2023
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Mesothelioma: Pleural, 2023

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...